Quantbot Technologies LP raised its holdings in Maximus, Inc. (NYSE:MMS – Free Report) by 738.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,628 shares of the health services provider’s stock after acquiring an additional 11,122 shares during the quarter. Quantbot Technologies LP’s holdings in Maximus were worth $1,176,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors also recently bought and sold shares of MMS. V Square Quantitative Management LLC purchased a new position in shares of Maximus in the 3rd quarter valued at about $25,000. GAMMA Investing LLC grew its position in Maximus by 224.5% during the second quarter. GAMMA Investing LLC now owns 344 shares of the health services provider’s stock worth $29,000 after buying an additional 238 shares during the period. Blue Trust Inc. increased its holdings in Maximus by 201.5% in the second quarter. Blue Trust Inc. now owns 392 shares of the health services provider’s stock valued at $33,000 after buying an additional 262 shares in the last quarter. Archer Investment Corp lifted its position in shares of Maximus by 8,788.9% during the 2nd quarter. Archer Investment Corp now owns 800 shares of the health services provider’s stock valued at $69,000 after acquiring an additional 791 shares during the period. Finally, Ariadne Wealth Management LP purchased a new stake in shares of Maximus during the 2nd quarter worth approximately $90,000. Institutional investors and hedge funds own 97.21% of the company’s stock.
Maximus Price Performance
Maximus stock opened at $74.50 on Friday. The firm has a market capitalization of $4.49 billion, a PE ratio of 14.90 and a beta of 0.77. Maximus, Inc. has a 52 week low of $71.75 and a 52 week high of $93.97. The firm’s 50-day simple moving average is $86.50 and its 200 day simple moving average is $87.57. The company has a quick ratio of 1.49, a current ratio of 1.49 and a debt-to-equity ratio of 0.59.
Maximus Announces Dividend
Wall Street Analysts Forecast Growth
Separately, StockNews.com downgraded Maximus from a “buy” rating to a “hold” rating in a research note on Thursday.
Insider Transactions at Maximus
In other Maximus news, insider Michelle F. Link sold 1,363 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $92.56, for a total transaction of $126,159.28. Following the sale, the insider now owns 6,567 shares in the company, valued at approximately $607,841.52. This represents a 17.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.40% of the company’s stock.
Maximus Profile
Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.
See Also
- Five stocks we like better than Maximus
- How to invest in marijuana stocks in 7 steps
- ServiceNow: Will the High-Flyer Finally Split in 2024?
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- MarketBeat Week in Review – 11/25 – 11/29
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- These 3 Stocks Are Heavy Hitters in Alternative Asset Management
Want to see what other hedge funds are holding MMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Maximus, Inc. (NYSE:MMS – Free Report).
Receive News & Ratings for Maximus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus and related companies with MarketBeat.com's FREE daily email newsletter.